The first indication of efficacy for FMT in human metabolic diseases was published in 2012, where in a pilot study in the Netherlands, in nine male adults with metabolic syndrome who received FMT from a lean donor, insulin resistance was improved, whereas no changes were observed in nine controls who received autologous FMT [8]. The gene discussed is INS; the disease is Other metabolic disease.